21.59USDMkt Cap: 442.14M USDP/E: —Last update: 2026-05-22
Forte Biosciences, Inc. operates as a clinical-stage biopharmaceutical company in the United States. The company's lead product candidate is the FB-102, a proprietary anti-CD122 monoclonal antibody therapeutic candidate …
Industry Peers
Biotechnologyloading…
Indicators:|
Key Statistics
Company
Market Cap442.14M USD
Enterprise Value479.36M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-69.38M USD
Revenue/Share—
Last Price21.59 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees19
CountryUS
SectorHealthcare
IndustryBiotechnology
ISINUS34962G1094
Valuation
P/E (Trailing)—
P/E (Forward)-5.31
PEG—
EV/EBITDA-6.23
EV/Revenue—
P/S—
P/B7.27
EPS (TTM)-4.58
EPS (Forward)-4.14
52W Range
20.6954% of range22.35
52W High22.35 USD
52W Low20.69 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-113.75%
ROA-83.81%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-50.88M USD
CapEx (TTM)116.00K USD
FCF Margin—
FCF Yield-7.07%
Net Debt-58.22M USD
Net Debt/EBITDA0.76
Balance Sheet
Debt/Equity—
Current Ratio2.75
Quick Ratio2.49
Book Value/Sh3.026 USD
Cash/Share2.383 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay DateJun 16, 2020
Splits
Last Split1:25
Split DateAug 28, 2024
Analyst Consensus
Rating1.0 (Strong Buy)
Target (Mean)63.75 USD
Target Range54.00 USD – 75.00 USD
# Analysts4
Ownership
Shares Out.20.48M
Float18.83M
Insiders2.15%
Institutions70.55%
Short Interest
Short Ratio2.6d
Short % Float5.10%
Short % Out.5.06%
Shares Short1.04M
Short (prev mo.)892.18K
Technical
SMA 5026.97 (-19.9%)
SMA 20021.64 (-0.2%)
Beta3.00
S&P 52W Chg28.31%
Avg Vol (30d)123.95K
Avg Vol (10d)251.75K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—